Harvard study links Ozempic and Wegovy to increased risk of rare vision loss (NAION) in diabetic and overweight/obese patients.

Harvard study links popular diabetes and weight-loss drugs Ozempic and Wegovy to increased risk of rare vision loss, called non-arteritic anterior ischemic optic neuropathy (NAION). Diabetic patients on semaglutide had a 4.28-fold higher risk, while overweight/obese patients taking the drug had a 7.64-fold higher risk of developing the condition, which can cause sudden, painless vision loss in one eye. The study, published in JAMA Ophthalmology, suggests more research is needed to confirm a causal link between the drugs and the condition.